Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
Teriparatide (PTH 1-34)
Active fragment of parathyroid hormone with anabolic bone activity
Read the monograph| Property | Teriparatide (PTH 1-34) | Abaloparatide |
|---|---|---|
| Class | PTH analogue | PTHrP analogue |
| Research category | severe osteoporosis | high-risk osteoporosis |
| Evidence level | High | High |
| Overall status | Approved (Rx) — osteoporosis at high fracture risk | Approved (Rx, FDA/EMA) — osteoporosis |
| FDA | Approved (Rx) | Approved (Rx) |
| EMA | Approved (Rx) | Approved (Rx) |
| WADA | Check current list | Check current list |
| Mechanism studied | Teriparatide → PTH1 receptor → Osteoblast activation → Bone formation | Abaloparatide → PTH1R (RG conformation) → Osteoblast activation → Bone formation |
| Molecular weight | 4,118 g/mol | 3,961 g/mol |
| Sizes in stock | Not currently listed | Not currently listed |
Where the research overlaps
Both compounds are studied within Endocrine research. Teriparatide (PTH 1-34) is classed as pth analogue, while Abaloparatide is pthrp analogue. Evidence is rated high for Teriparatide (PTH 1-34) and high for Abaloparatide.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.